Breakthrough discovery of a novel mechanism targeting monoamine pathways with enhanced selectivity
for CNS disorders, published in leading neuroscience journals.
2024
Advanced Preclinical Models
Development of sophisticated behavioral and neurobiological models for accurate prediction of
clinical efficacy in Alzheimer's disease and depression.
2024
Biomarker Discovery Program
Identification of novel CNS biomarkers for patient stratification and treatment response prediction,
enabling personalized medicine approaches.
2023-2024
Drug Formulation Optimization
Proprietary formulation technology improving brain penetration and reducing adverse effects for
optimal therapeutic outcomes.